Observer prediction of HER2 amplification in HercepTest 2+ breast cancers as a potential audit instrument

  • Going J
  • 7

    Readers

    Mendeley users who have this article in their library.
  • 3

    Citations

    Citations of this article.

Abstract

Going J J (2011) Histopathology59, 333-335 Observer prediction of HER2 amplification in HercepTest 2+ breast cancers as a potential audit instrument Aims:  Correct assignment of human epidermal growth factor receptor 2 (HER2) status in breast cancer is important. Indeterminate (2+) HER2 immunohistochemistry (IHC) is usually resolved by FISH for HER2 gene amplification. It was hypothesised that predicting HER2 amplification in IHC 2+ cases could improve audit of HER2 IHC and its interpretation. Methods and results:  One observer (J. J. G.) interpreted 4343 assessable HercepTests on consecutive breast cancers from the West of Scotland over 45 consecutive months during 2007-2010, with 2+ cases classified prospectively as 'probably amplified', 'possibly amplified' or 'probably not amplified' prior to FISH. A HER2 to chromosome 17 FISH ratio >2 was taken to define HER2 amplification. There were 265 3+ cases (6.1%) and 883 2+ cases (20.3%). Of 187 'probably amplified' 2+ cases, 166 (88.8%) were amplified, as were 90 (37.8%) of 238 'possibly amplified' 2+ cases. Of 458 'probably not amplified' but still 2+ cases, 59 (12.8%) were in fact amplified (overall χ(2) 333.89, df 2, P 

Author-supplied keywords

  • Breast cancer
  • FISH
  • HER2
  • Immunohistochemistry

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • James J. Going

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free